TY - JOUR
T1 - Test-retest resting-state fMRI in healthy elderly persons with a family history of Alzheimer's disease
AU - The PREVENT-AD Research Group
AU - Orban, Pierre
AU - Madjar, Cécile
AU - Savard, Mélissa
AU - Dansereau, Christian
AU - Tam, Angela
AU - Das, Samir
AU - Evans, Alan C.
AU - Rosa-Neto, Pedro
AU - Breitner, John C.S.
AU - Bellec, Pierre
AU - Aisen, Paul
AU - Pascoal, Tharick Ali
AU - Anthal, Elena
AU - Appleby, Melissa
AU - Barkun, Alan
AU - Beaudry, Thomas
AU - Benbouhoud, Fatiha
AU - Bohbot, Veronique
AU - Brandt, Jason
AU - Brunelle, Céline
AU - Carmo, Leopoldina
AU - Cheewakriengkrai, Laksanaun
AU - Collins, Louis
AU - Courcot, Blandine
AU - Couture, Doris
AU - Craft, Suzanne
AU - Cuello, A. Claudio
AU - Dadar, Mahsa
AU - Dauar-Tedeschi, Marina
AU - Dea, Dorothy
AU - Debacker, Clément
AU - Desautels, René
AU - Desrochers, Nicole
AU - Dubuc, Sylvie
AU - Duclair, Guerda
AU - Dufour, Marianne
AU - Eisenberg, Mark
AU - El-Khoury, Rana
AU - Etienne, Pierre
AU - Faubert, Anne Marie
AU - Ferdinand, Fabiola
AU - Fonov, Vladimir S.
AU - Fontaine, David
AU - Francoeur, Renaud
AU - Frappier, Josée
AU - Frenette, Joanne
AU - Gauthier, Serge
AU - Gervais, Valérie
AU - Jack, Clifford R.
AU - Knopman, David S.
PY - 2015/10/13
Y1 - 2015/10/13
N2 - We present a test-retest dataset of resting-state fMRI data obtained in 80 cognitively normal elderly volunteers enrolled in the "Pre-symptomatic Evaluation of Novel or Experimental Treatments for Alzheimer's Disease" (PREVENT-AD) Cohort. Subjects with a family history of Alzheimer's disease in first-degree relatives were recruited as part of an on-going double blind randomized clinical trial of Naproxen or placebo. Two pairs of scans were acquired ∼3 months apart, allowing the assessment of both intra- and inter-session reliability, with the possible caveat of treatment effects as a source of inter-session variation. Using the NeuroImaging Analysis Kit (NIAK), we report on the standard quality of co-registration and motion parameters of the data, and assess their validity based on the spatial distribution of seed-based connectivity maps as well as intra- and inter-session reliability metrics in the default-mode network. This resource, released publicly as sample UM1 of the Consortium for Reliability and Reproducibility (CoRR), will benefit future studies focusing on the preclinical period preceding the appearance of dementia in Alzheimer's disease.
AB - We present a test-retest dataset of resting-state fMRI data obtained in 80 cognitively normal elderly volunteers enrolled in the "Pre-symptomatic Evaluation of Novel or Experimental Treatments for Alzheimer's Disease" (PREVENT-AD) Cohort. Subjects with a family history of Alzheimer's disease in first-degree relatives were recruited as part of an on-going double blind randomized clinical trial of Naproxen or placebo. Two pairs of scans were acquired ∼3 months apart, allowing the assessment of both intra- and inter-session reliability, with the possible caveat of treatment effects as a source of inter-session variation. Using the NeuroImaging Analysis Kit (NIAK), we report on the standard quality of co-registration and motion parameters of the data, and assess their validity based on the spatial distribution of seed-based connectivity maps as well as intra- and inter-session reliability metrics in the default-mode network. This resource, released publicly as sample UM1 of the Consortium for Reliability and Reproducibility (CoRR), will benefit future studies focusing on the preclinical period preceding the appearance of dementia in Alzheimer's disease.
UR - http://www.scopus.com/inward/record.url?scp=84958022180&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84958022180&partnerID=8YFLogxK
U2 - 10.1038/sdata.2015.43
DO - 10.1038/sdata.2015.43
M3 - Article
C2 - 26504522
AN - SCOPUS:84958022180
SN - 2052-4463
VL - 2
JO - Scientific Data
JF - Scientific Data
M1 - 150043
ER -